BioSpace News Archive

Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (“Agreement”) regarding Acura’s LIMITx™ LTX-03 product candidate with Abuse Deterrent Pharma, LLC (“AD Pharma”) to extend the FDA Acceptance Date for LTX-03 (“NDA Acceptance Date”) to February 28, 2022.

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced a partnership agreement with Biocon Biologics Ltd., to combat the ongoing COVID-19 crisis in southern Asia.

Medpace Holdings, Inc. announced the appointment of Jesse Geiger as president and Kevin Brady as chief financial officer, effective August 1, 2021.

Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, August 9, at 4:30 p.m. EDT to provide a corporate update and discuss financial results for the second quarter ended June 30, 2021.

Medpace Holdings, Inc. announced financial results for the second quarter ended June 30, 2021.

Universal Health Services, Inc. (NYSE: UHS) announced today that its reported net income attributable to UHS was $325.0 million, or $3.79 per diluted share, during the second quarter of 2021, as compared to $251.9 million, or $2.95 per diluted share, during the second quarter of 2020

Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that topline data from a Phase 1b placebo-controlled, multiple ascending dose clinical study showed that BIIB080/IONIS-MAPTRx met its primary objective of safety and tolerability in patients with mild Alzheimer’s disease.

ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-cancer therapies, today announced that Dr. Revati Shreeniwas has joined the company as Chief Medical Officer.

Kiromic Biopharma, Inc. (Nasdaq: KRBP), a pioneer in immuno oncology cellular therapy in solid tumors, is pleased to announce it has completed the acquisition of InSilico Solutions.

Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, today announced positive initial results from a Phase 1b proof-of-concept study evaluating CERC-002,